Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Liabilities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Total Liabilities for 16 consecutive years, with $23.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 11.68% to $23.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.8 million through Dec 2025, down 11.68% year-over-year, with the annual reading at $23.8 million for FY2025, 11.68% down from the prior year.
  • Total Liabilities for Q4 2025 was $23.8 million at Gyre Therapeutics, up from $22.0 million in the prior quarter.
  • The five-year high for Total Liabilities was $38.1 million in Q4 2023, with the low at $1.6 million in Q3 2022.
  • Average Total Liabilities over 5 years is $18.4 million, with a median of $17.2 million recorded in 2021.
  • The sharpest move saw Total Liabilities plummeted 90.76% in 2022, then surged 315.17% in 2024.
  • Over 5 years, Total Liabilities stood at $14.6 million in 2021, then dropped by 13.98% to $12.5 million in 2022, then skyrocketed by 203.65% to $38.1 million in 2023, then decreased by 29.06% to $27.0 million in 2024, then decreased by 11.68% to $23.8 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $23.8 million, $22.0 million, and $23.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.